Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma

Kamamoto, Dai; Saga, Isako; Ohara, Kentaro; Yoshida, Kazunari; Sasaki, Hidenao

doi:10.1016/j.wneu.2018.12.067

Cited by 13 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-grade tumors were often accompanied by a high degree of malignancy and strong invasiveness, which has an adverse impact on the prognosis of patients (23). Simultaneously, increased expression of CD133 and nestin in high-grade tumor tissues lead to an increase of cell atypia and reduced effectiveness of medical treatment (23). In our study, the pathological grade of tumors as an independent prognostic factor influenced the survival of RCC patients with bone metastasis.…”

Section: Discussionmentioning

confidence: 55%

“…The pathological grade of the tumor was positively correlated with the stemness of the cancer cells (22). High-grade tumors were often accompanied by a high degree of malignancy and strong invasiveness, which has an adverse impact on the prognosis of patients (23). Simultaneously, increased expression of CD133 and nestin in high-grade tumor tissues lead to an increase of cell atypia and reduced effectiveness of medical treatment (23).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Wang

et al. 2021

Int. braz j urol.

View full text Add to dashboard Cite

Purpose: Increased attention has been focused on the survival of renal cell carcinoma (RCC) patients with bone metastasis. This study proposed to establish and evaluate a nomogram for predicting the overall survival (OS) and cancer-specific survival (CSS) of RCC patients with bone metastasis. Materials and Methods: RCC patients with bone metastasis between 2010 and 2015 were captured from the surveillance, epidemiology and end results (SEER) database. Univariate and multivariate cox regressions were performed to assess the effects of clinical variables on OS and CSS. The nomogram based on the Cox hazards regression model was developed. Concordance index (C-index) and calibration curve were performed to evaluate the accuracy of nomogram models, receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were conducted to assess the predict performance. Results: A total of 2.471 eligible patients were enrolled in this study. The patients were assigned to primary (n=1.672) and validation (n=799) cohorts randomly. The 1-, 2-, and 3-year OS and CSS nomogram models were constructed based on age at diagnosis, sex, marital status, pathological grade, T-stage, N-stage, brain/liver/lung metastasis, surgery, radiotherapy and chemotherapy. The c for OS and CSS prediction was 0.730 (95% confidence interval [CI]: 0.719-0.741) and 0.714 (95%CI:0.702-0.726). The calibration curves showed significant agreement between nomogram models and actual observations. ROC and DCA indicated nomograms had better predict performance. Conclusions: The nomograms for predicting prognosis provided an accurate prediction of OS and CSS in RCC patients with bone metastasis, and contributed clinicians to optimize individualized treatment plans.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Wang

et al. 2021

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

“…On the contrary, expression of Nestin and hTERT varied across cell lines, although both showed significantly strong expression in the transitional meningioma cell line M3. The expression of Nestin and hTERT has been reported to be closely correlated to progression and recurrence in meningioma [41,42]. Therefore, the higher expression level of Nestin and hTERT in M3 cell lines might suggest a higher probability of recurrence after surgery.…”

Section: Discussionmentioning

confidence: 99%

Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors

Kim

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Meningiomas are the second most common primary tumors of the central nervous system. However, there is a paucity of data on meningioma biology due to the lack of suitable preclinical in vitro and in vivo models. In this study, we report the establishment and characterization of patient-derived, spontaneously immortalized cancer cell lines derived from World Health Organization (WHO) grade I and atypical WHO grade II meningiomas. Methods: We evaluated high-resolution 3T MRI neuroimaging findings in meningioma patients which were followed by histological analysis. RT-qPCR and immunostaining analyses were performed to determine the expression levels of meningioma-related factors. Additionally, flow cytometry and sorting assays were conducted to investigate and isolate the CD133 and CD44 positive cells from primary atypical meningioma cells. Further, we compared the gene expression profiles of meningiomas and cell lines derived from them by performing whole-exome sequencing of the blood and tumor samples from the patients, and the primary cancer cell lines established from the meningioma tumor. Results: Our results were consistent with earlier studies that reported mutations in NF2, SMO, and AKT1 genes in atypical meningiomas, and we also observed mutations in MYBL2, a gene that was recently discovered. Significantly, the genomic signature was consistent between the atypical meningioma cancer cell lines and the tumor and blood samples from the patient. Conclusion: Our results lead us to conclude that established meningioma cell lines with a genomic signature identical to tumors might be a valuable tool for understanding meningioma tumor biology, and for screening therapeutic agents to treat recurrent meningiomas.

show abstract

“…Malta et al established an index based on the stemness markers indicating the cancer stem cell proportion in the given tumor sample [ 21 ]. Although the cancer stem cells are yet to be isolated from meningioma, cancer stem cell and embryonic stem cell markers have been widely identified from meningiomas and strongly associated with patients outcomes [ 24 , 25 ]. To infer the proportion of cancer stem cells between subtypes of meningiomas, we utilized a reference-based matrix to generate stemness indexes (SIs) for each meningioma in our study.…”

Section: Resultsmentioning

confidence: 99%

MPscore: A Novel Predictive and Prognostic Scoring for Progressive Meningioma

Liu

Qian

2021

Cancers

View full text Add to dashboard Cite

Meningioma is the most common tumor in central nervous system (CNS). Although most cases of meningioma are benign (WHO grade I) and curable by surgical resection, a few tumors remain diagnostically and therapeutically challenging due to the frequent recurrence and progression. The heterogeneity of meningioma revealed by DNA methylation profiling suggests the demand of subtyping for meningioma. Therefore, we performed a clustering analyses to characterize the progressive features of meningioma and constructed a meningioma progression score to predict the risk of the recurrence. A total of 179 meningioma transcriptome from RNA sequencing was included for progression subtype clustering. Four biologically distinct subtypes (subtype 1, subtype 2, subtype 3 and subtype 4) were identified. Copy number alternation and genomewide DNA methylation of each subtype was also characterized. Immune cell infiltration was examined by the microenvironment cell populations counter. All anaplastic meningiomas (7/7) and most atypical meningiomas (24/32) are enriched in subtype 3 while no WHO II or III meningioma presents in subtype 1, suggesting subtype 3 meningioma is a progressive subtype. Stemness index and immune response are also heterogeneous across four subtypes. Monocytic lineage is the most immune cell type in all meningiomas, except for subtype 1. CD8 positive T cells are predominantly observed in subtype 3. To extend the clinical utility of progressive meningioma subtyping, we constructed the meningioma progression score (MPscore) by the signature genes in subtype 3. The predictive accuracy and prognostic capacity of MPscore has also been validated in three independent cohort. Our study uncovers four biologically distinct subtypes in meningioma and the MPscore is potentially helpful in the recurrence risk prediction and response to treatments stratification in meningioma.

show abstract

Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma

Cited by 13 publications

References 31 publications

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors

MPscore: A Novel Predictive and Prognostic Scoring for Progressive Meningioma

Contact Info

Product

Resources

About